Company: WHWK
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023932
Chunk: 267

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 267
---
2021 Plan (unless the 2021 Plan has terminated). 

18

2023 Inducement Equity Incentive PlanOn September 27, 2023 the Company adopted the 2023 Inducement Equity Incentive Plan (the “Inducement Plan”), pursuant to which the Company may from time to time make equity grants to new employees as a material inducement to their employment. The Company reserved 600,000 shares of common stock for issuance under the Inducement Plan. The only persons eligible to receive awards under the Inducement Plan are individuals who are new employees and satisfy the standards for inducement grants under applicable Nasdaq listing rules.As of March 31, 2025, 161,534, 15,036, 4,660,249, and 490,000 shares were outstanding under the Private Aadi Plan, 2017 Plan, 2021 Plan, and 2023 Inducement Plan, respectively. The following table summarizes the stock option activity during the three months ended March 31, 2025: StockOptionSharesWeighted AverageExercisePriceWeighted AverageRemainingContractualTerm (in Years)AggregateIntrinsicValue (in thousands)Outstanding, December 31, 20244,950,016 $10.82 7.99$1,818 Granted687,979 2.31 Exercised(22,204)0.95 Cancelled/Forfeited(288,972)11.52 Outstanding as of March 31, 20255,326,819 $9.72 8.06$29 Options exercisable as of March 31, 20252,996,934 $13.26 7.41$— Vested and expected to vest as of March 31, 20255,326,819 $9.72 8.06$29 As of March 31, 2025, there was $8.4 million of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted average period of 1.92 years.The total intrinsic value of the options exercised during the three months ended March 31, 2025, and 2024, was $43,000 and $0, respectivelyAs of March 31, 2025, and December 31, 2024, 1,632,796 and 1,013,055 shares were reserved for